Every 8-K that Octave Specialty Group, Inc. (OSG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OSG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSG filings page.
Octave Specialty Group, Inc. reported second quarter 2026 results with total revenue of $83.0 million, up 51% from $55.0 million a year earlier, driven mainly by its Insurance Distribution segment and the 2025 ArmadaCare acquisition. Net loss attributable to shareholders narrowed to $(14.4) million, or $(0.33) per diluted share, compared with $(72.7) million, or $(1.51) per share, in 2025.
Adjusted EBITDA to shareholders turned positive at $3.7 million versus a $(4.6) million loss, and adjusted net loss improved to $(1.8) million from $(10.6) million. Insurance Distribution revenue rose 77% to $58.4 million with organic revenue growth of 44.1%, while Adjusted EBITDA to shareholders climbed to $9.8 million from $2.5 million. Specialty P&C insurer Everspan generated net income of $1.1 million, improved its loss ratio to 61.4%, and reduced its combined ratio to 100.6%.
For the first half of 2026, total revenue reached about $187.2 million, and adjusted net income attributable to shareholders was $14.8 million. Stockholders’ equity attributable to common shareholders was $699 million, or $15.52 per share as of June 30, 2026. Octave also highlighted new data and AI initiatives, including a proprietary AI-driven underwriting platform, and scheduled an August 7, 2026 earnings call to discuss results and updated 2026 guidance.
Octave Specialty Group, Inc. held its annual meeting of stockholders on May 28, 2026, with 36,679,356 shares represented, about 81% of the 45,013,592 common shares entitled to vote. Stockholders elected seven directors to terms expiring at the 2027 annual meeting. They also approved, on an advisory basis, the compensation of named executive officers, ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approved the Company’s 2026 Incentive Compensation Plan.
Octave Specialty Group, Inc. reported much stronger first quarter 2026 performance, driven by its Insurance Distribution segment, while still posting a small GAAP loss. Total revenues from continuing operations rose 66% to $104.2 million, compared with $62.8 million a year earlier.
Net loss attributable to shareholders from continuing operations narrowed to $(6.9) million, or $(0.13) per diluted share, from $(16.1) million, or $(0.57) per share. On a non-GAAP basis, adjusted net income attributable to shareholders improved to $16.6 million versus an adjusted net loss of $(6.0) million, and adjusted EBITDA to shareholders increased to $20.1 million from $(1.3) million.
The Insurance Distribution segment generated total revenue of $78.5 million, up 92%, with organic revenue growth of 41.8% and adjusted EBITDA to shareholders of $25.3 million. The Specialty P&C Insurance segment grew premiums but recorded a $7.7 million net loss and a 149.7% combined ratio due in part to losses and legal expenses from settling a potential litigation matter on a run-off program.
Octave Specialty Group, Inc. entered into a First Amendment to its Credit Agreement that provides an additional term loan in an aggregate principal amount of $40,000,000. This Additional Term Loan has the same maturity date, interest rate and tranche as the existing term loan and is fully fungible with it.
After this amendment, total outstanding term loans are $139,375,000 as of April 1, 2026. In connection with the amendment, the company pledged its ownership interests in the capital stock of Everspan Holdings, LLC. The proceeds will help fund Cirrata UK’s obligation to honor put rights exercised by certain minority shareholders of Octave Specialty Limited.
Octave Specialty Group reported modest growth but continued losses in fourth quarter 2025. Total revenue from continuing operations was $67 million, up 3% from $65 million a year earlier, driven mainly by the Insurance Distribution segment, which achieved 8.1% organic revenue growth.
Net loss from continuing operations attributable to shareholders widened to $30 million from $22 million, reflecting ArmadaCare acquisition costs, expenses tied to exiting the financial guarantee business, and an investment impairment. Adjusted EBITDA to shareholders improved to $1.4 million from $0.5 million, as higher distribution earnings and early cost reductions partially offset weakness in specialty P&C.
For full-year 2025, revenue from continuing operations reached $251.2 million, up 7%, while net loss from continuing operations attributable to shareholders increased to $98.4 million. The company repurchased over 3.1 million shares, or 6.7% of shares outstanding, and ended December 31, 2025 with stockholders’ equity of $715.8 million, or $15.90 per share.